SCHEMBL20119446

SCHEMBL20119446

CC(=O)NCCn1ccc2c(NCc3ccco3)nc(Cl)nc21

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MTNR1A P48039 4/20 0.45
CYP3A4 P08684 1/20 0.45
CYP2D6 P10635 1/20 0.45
CYP2C9 P11712 1/20 0.45
TSHR P16473 1/20 0.45
CYP2C19 P33261 1/20 0.45
MTNR1B P49286 3/20 0.43
KMT2A Q03164 3/20 0.43
SMN1; SMN2 Q16637 1/20 0.42
MAPK1 P28482 1/20 0.41
NPC1 O15118 1/20 0.41
F2 P00734 1/20 0.41
RAB9A P51151 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
HRH4 Q9H3N8 3/20 0.40
MAPT P10636 2/20 0.40
ALDH1A1 P00352 1/20 0.40
REN P00797 1/20 0.39
KDM4E B2RXH2 1/20 0.39
LMNA P02545 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20119912 0.87 SMN1; SMN2 (0.46) CYP2C9KMT2ASMN1; SMN2MAPK1NPSR1
SCHEMBL20119724 0.84 KMT2A (0.52) KMT2ASMN1; SMN2MAPK1NPSR1HRH4
SCHEMBL20119378 0.83 KMT2A (0.51) KMT2ASMN1; SMN2MAPK1NPC1RAB9A
SCHEMBL20119403 0.83 SMN1; SMN2 (0.48) KMT2ASMN1; SMN2MAPK1NPC1RAB9A
SCHEMBL20119908 0.83 SMN1; SMN2 (0.46) TSHRKMT2ASMN1; SMN2MAPK1NPSR1
SCHEMBL20119774 0.82 SMN1; SMN2 (0.43) KMT2ASMN1; SMN2MAPK1NPC1F2
SCHEMBL20119351 0.82 SMN1; SMN2 (0.45) KMT2ASMN1; SMN2MAPK1NPSR1HRH4
SCHEMBL20119634 0.82 LMNA (0.45) KMT2ASMN1; SMN2MAPK1NPSR1HRH4
SCHEMBL20119900 0.81 SMN1; SMN2 (0.43) KMT2ASMN1; SMN2MAPK1NPC1F2
SCHEMBL20119712 0.80 SMN1; SMN2 (0.45) KMT2ASMN1; SMN2MAPK1NPSR1HRH4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230279007-A1 Compounds for Improving mRNA Splicing THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES 2023-09-07 US disclosed
US-11702417-B2 Compounds for improving mRNA splicing THE GENERAL HOSPITAL CORPORATION (US) 2023-07-18 US disclosed
US-20200283441-A1 Compounds for Improving mRNA Splicing THE GENERAL HOSPITAL CORPORATION 2020-09-10 US disclosed
US-10676475-B2 Compounds for improving mRNA splicing THE GENERAL HOSPITAL CORPORATION (US) 2020-06-09 US disclosed
US-20180118748-A1 Compounds for Improving mRNA Splicing THE GENERAL HOSPITAL CORPORATION 2018-05-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230279007-A1 Compounds for Improving mRNA Splicing RTCB, RBM17, HNRNPA2B1 MTNR1A 2031/4885CYP3A4 4281/4885CYP2D6 3804/4885
US-10676475-B2 Compounds for improving mRNA splicing RTCB, RBM17, HNRNPA2B1 MTNR1A 2031/4885CYP3A4 4281/4885CYP2D6 3804/4885
US-20180118748-A1 Compounds for Improving mRNA Splicing RTCB, RBM17, HNRNPA2B1 MTNR1A 2031/4885CYP3A4 4281/4885CYP2D6 3804/4885
US-11702417-B2 Compounds for improving mRNA splicing RTCB, RBM17, HNRNPA2B1 MTNR1A 2031/4885CYP3A4 4281/4885CYP2D6 3804/4885
US-20200283441-A1 Compounds for Improving mRNA Splicing RTCB, RBM17, HNRNPA2B1 MTNR1A 2031/4885CYP3A4 4281/4885CYP2D6 3804/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.